多中心队列研究中髂股静脉疾病支架通畅性的预测因素
该多中心队列纳入2014年1月至2020年12月七家医院377例下肢静脉血栓病史并接受髂或股总静脉支架的患者,比较非血栓性髂静脉病变(NIVL)、急性深静脉血栓(aDVT)和血栓后综合征(PTS)三组的支架通畅性预测因素。NIVL组一期通畅率99.3%,显著高于PTS组68.6%(p < .001)和aDVT组83.6%(p = .002);aDVT组中支架置入前长期抗凝是通畅性更差的唯一预测因素。
要点
- NIVL组一期通畅率99.3%,高于PTS组68.6%(p < .001)和aDVT组83.6%(p = .002)。
- PTS组支架数量显著更多(p < .001),腹股沟韧带以下支架更多(p < .001)。
- aDVT组中支架置入前长期抗凝是通畅性更差的唯一预测因素。
核心结论
- NIVL患者静脉支架置入后一期通畅率优于静脉血栓性疾病患者。
- aDVT患者中支架置入前长期抗凝是唯一与更差一期通畅性相关的因素。
研究设计与样本
- 多中心队列研究,纳入2014年1月至2020年12月七家医院连续的下肢静脉血栓病史并接受髂或股总静脉支架置入的患者。
- 共纳入377例患者:NIVL 134例、aDVT 55例、PTS 188例,均至少有六个月随访及支架影像学检查。
- 报告并比较静脉支架置入后抗凝和抗血小板治疗策略。
主要发现
- NIVL组一期通畅率99.3%,PTS组68.6%(p < .001),aDVT组83.6%(p = .002)。
- PTS组支架数量显著更多(p < .001),腹股沟韧带以下支架更多(p < .001)。
- 中位随访28.8个月(IQR 16, 47)。
- 末次评估时停用抗凝治疗比例:NIVL组93.2%、aDVT组25.0%、PTS组70.3%(p < .001)。
关键数值与推荐
- aDVT组中支架置入前长期抗凝是唯一与更差一期通畅性相关的预测因素。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This study assessed primary stent patency predictive factors in three groups of patients with history of lower limb (LL) vein thrombosis: non-thrombotic iliac vein lesion (NIVL), acute deep vein thrombosis (aDVT), and post-thrombotic syndrome (PTS). METHODS: Consecutive patients from January 2014 to December 2020 with history of LL vein stenting from seven hospitals were included. All patients received an iliac or common femoral venous stent and had at least a six month follow up available with stent imaging. Anticoagulant and antiplatelet therapy strategies employed after venous stenting are reported and compared between groups. RESULTS: This study included 377 patients: 134 NIVL, 55 aDVT, and 188 PTS. Primary patency was statistically significantly higher in the NIVL group (99.3%) compared with the PTS group (68.6%) (p < .001) and the aDVT group (83.6%) (p = .002). PTS patients received a statistically significantly greater number of stents (p < .001) and had more stents below the inguinal ligament (p < .001). Median follow up was 28.8 months (IQR 16, 47). Discontinuation of antiplatelet therapy at the last assessment was 83.6% for NIVL, 100% for aDVT, and 95.7% for the PTS group (p < .001). Discontinuation of anticoagulation therapy at the last assessment was 93.2% for NIVL, 25.0% for aDVT, and 70.3% for the PTS group (p < .001). The only predictor of worse primary patency in the aDVT group was long term anticoagulation before stenting. CONCLUSION: Patients with NIVL have better primary patency after venous stenting than patients with venous thrombotic disorders. Long term anticoagulation before stenting was the only factor associated with poorer primary patency in patients with aDVT.
引用
- Espitia O, Douane F, Hersant J, et al. Predictive Factors of Stent Patency in Iliofemoral Venous Diseases in a Multicentre Cohort Study. Eur J Vasc Endovasc Surg. 2023. PMID: 36642400. doi:10.1016/j.ejvs.2023.01.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。